#1signifyhealth. Fourth Quarter and Full Year 2021 Earnings Summary March 3, 2022 Homeward.#2→→> Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical fact included in this presentation are forward-looking statements. These statements may be preceded by, followed by or include the words "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business, our plan to drive better patient outcomes, our 2022 Outlook, including our 2022 estimates for total GAAP revenue, total Adjusted EBITDA, in-home evaluations, bundled payment program size and bundled payment weighted average savings rate improvements. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include: our failure to maintain and grow our network of high-quality network providers; the COVID-19 pandemic and whether the pandemic will continue to subside in 2022; factors beyond our control that could impact our ability to complete IHES; our dependence upon a limited number of key customers; our dependence on certain key government programs including BPCI-A; risks associated with estimating program size and savings rate in BPCI-A; ; our failure to continue to innovate and provide services that are useful to customers and achieve and maintain market acceptance; our limited operating history with certain of our solutions; our failure to compete effectively; the length and unpredictability of our sales cycle; seasonality that may cause fluctuations in our sales, cash flows and results of operations; the information we provide to, or receive from, our health plans and providers could be inaccurate or incomplete; the risk that the cost of services provided will be higher than benchmark prices in our episodes and care redesign solutions; risks that arise from operating internationally; failure of our existing customers to continue or renew their contracts with us; failure of service providers to meet their obligations to us; ; our failure to achieve or maintain profitability; our revenue not growing at the rates they historically have, or at all; our failure to successfully execute on our growth initiatives, business strategies, or operating plans, including growth in our Commercial Episodes business; our failure to successfully launch new products; our failure to diversify sources of revenues and earnings; inaccurate estimates and assumptions used to determine the size of our total addressable market; changes in accounting principles applicable to us; incorrect estimates or judgments relating to our critical accounting policies; increases in our level of indebtedness; our failure to effectively adapt to changes in the healthcare industry, including changes in the rules governing Medicare or other federal healthcare programs; our failure to adhere to complex and evolving governmental laws and regulations; our failure to comply with current and future federal and state privacy, security and data protection laws, regulations or standards; our employment of and contractual relationships with our providers subjecting us to licensing or other regulatory risks, including recharacterization of our contracted providers as employees; adverse findings from inspections, reviews, audits and investigations from health plans; inadequate investment in or maintenance of our operating platform and other information technology and business systems; our ability to develop and/or enhance information technology systems and platforms to meet our changing customer needs; higher than expected investments in our business including, but not limited to, investments in our technology and operating platform, which could reduce our profitability; security breaches or incidents, loss or misuse of data, a failure in or breach of our operational or security systems or other disruptions; disruptions in our disaster recovery systems or management continuity planning; our ability to comply with, and changes to, laws, regulations and standards relating to privacy or data protection; our ability to obtain, maintain, protect and enforce our intellectual property; our dependence on distributions from Cure TopCo, LLC to fund dividend payments, if any, and to pay our taxes and expenses, including payments under the Tax Receivable Agreement; the control certain equity holders that held an ownership interest in Cure TopCo, LLC prior to our IPO have over us and our status as a controlled company; our ability to realize any benefit from our organizational structure; and the other risk factors described under "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which are available free of charge on the SEC's website at: www.sec.gov. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws. This presentation contains certain financial measures not presented in accordance with generally accepted accounting principles in the United State ("GAAP"), including Adjusted EBITDA, which is used by management in making operating decisions, allocating financial resources, and internal planning and forecasting and for business strategy purposes. Adjusted EBITDA is not a measure of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, this measure should not be considered in isolation or as an alternative to GAAP measures. Our presentation of Adjusted EBITDA may not be comparable to similarly-titled measures used by other companies. Management believes that such measures are commonly reported by issuers and widely used by investors as indicators of a company's operating performance. There are other non-GAAP financial measures which should be considered only as a supplement to, and not as a superior measure to, financial measures prepared in accordance with GAAP. Please refer to the Appendix of this document for a reconciliation of Adjusted EBITDA to the most directly comparable financial measure prepared in accordance with GAAP. This presentation includes market and industry data and forecasts that we have derived from independent consultant reports, publicly available information, various industry publications, other published industry sources, and our internal data and estimates. Independent consultant reports, industry publications, and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. The inclusion of market estimations, rankings, and industry data in this presentation is based upon such reports, publications, and other sources and our internal data and estimates and our understanding of industry conditions. Although we believe that such information is reliable, we have not had this information verified by any independent sources. You are cautioned not to give undue weight to such estimates. All trademarks, service marks, and trade names appearing in this presentation are the property of their respective holders. signifyhealth. 2#3--> Full Year 2021 highlights Total Operations Revenue ● ● ● ● Home & Community Services ● Net Income Adjusted EBITDA (1) Adjusted EBITDA Margin (¹) ● Episodes of Care Services ● Revenue Adjusted EBITDA (1) Revenue Adjusted EBITDA (1) signifyhealth $ 773.4M $ 5.0M $ 171.2M 22.1% $ 653.1 M $ 195.2M $ 120.3M ($24.0)M ● 27% increase in revenue driven by strong HCS results 37% increase in adjusted EBITDA driven by HCS revenue 160 basis point increase in adjusted EBITDA Margin 45% increase in revenue and 103% increase in adjusted EBITDA due to strong in-home-evaluation volume of 1.92 million in 2021 25% reduction in revenue reflects adverse COVID-19 impact on program size and overall savings rate 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin 3#4Signify Health Total --> Full Year Results December 31, 2021 Total Revenue ($ in millions) signifyhealth. $611 2020 + 27% $773 2021 Total Adj. EBITDA(¹) ($ in millions) $125 2020 +37% 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin $171 2021 4#5--> Q4 2021 highlights Total Operations Revenue ● ● ● ● Net Income Adjusted EBITDA (1) Adjusted EBITDA Margin (¹) Home & Community Services Revenue Adjusted EBITDA (1) Episodes of Care Services Revenue Adjusted EBITDA (1) signifyhealth $181.4M $ 27.5M $ 40.2M 22.2% $156.2M $ 48.4M $25.2M ($8.2) M ● ● ● ● ● ● 6% decrease in revenue driven by ECS results, partially offset by strong HCS results Net income positively impacted by $36.7M in remeasurement of outstanding customer EARS 3% increase in adjusted EBITDA driven by continued strong operating performance, primarily growth in HCS revenue 200 basis point increase in adjusted EBITDA Margin 5% increase in revenue and 59% increase in adjusted EBITDA due to strong in-home-evaluation volume of ~473K which was flat compared to Q4 2020 44% reduction in revenue reflects adverse COVID-19 impact on program size and overall savings rate 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin 5#6--> Signify / Cararvan Health combination ● ● ● ● The One-Stop-Shop for Enablement in Value Based Payment Arrangements Leading convener and enabler of Episodes / Bundles Depth with health systems, hospitals and PGPs Strength in care redesign Strength in Post Acute Management and Transitions of Care homeward Ability to engage patients in the home at scale with both clinical and social care signifyhealth. signifyhealth. + Shared vision to transform how care is paid for and delivered CARAVANHEALTH Massive combined network of partners in VBC arrangements $10Bn spend under management +170 provider organizations in ACOS 6 Collaborative ACOS End-to-end VBC platform (BPCIA, MSSP, Commercial Episodes & ACO; Medicare FFS, MA, and Commercial) Primed to expand with payors and new models (Commercial, DC) ● Leading convener and enabler of Collaborative ACOS Depth with rural providers and community health systems Strength in practice transformation and pop health initiatives Expertise and growth in enabling providers in 340B 6#7--> MSSP (ACO) vs. BPCIA (Episodes) How do these voluntary risk models operate? ● ● ● • ● What are the major differences? BPCIA CMMI program Specific patients / conditions Focus on hospitals & specialists Org. keeps savings net of CMS discount Approx. 90-day period BPCIA Specialists & Hospitals select from 34 potential episodes signifyhealth. Provider manages all spend over 90 days following an acute event Target prices set prospectively and reconciled semi-annually ● ● Who "owns" the risk? ● MSSP Federally enacted All patients / conditions Focus on PCPs Org. shares savings with CMS Annual total cost of care MSSP Beneficiaries are attributed to the PCP that they see most often The PCP is responsible for all member spend in a given year • Benchmarks set prospectively and reconciled annually BPCIA MSSP O acute event How long is the risk period? 90-days post-acute All Medicare spend for attributed members over the course of a year BPCIA CMS discount Provider savings (100%) How are savings generated & shared? MSSP CMS share (25-60%) benchmark While BPCIA covers timeboxed episodes, MSSP covers all spend for attributed members over the course of a year target price Provider/convener earns all savings below target price Provider savings (40-75%) benchmark Provider and CMS share in all savings below the benchmark 7#82022 Guidance Total Revenue Total adjusted EBITDA(1) $948 $971 M signifyhealth $212-222 M Includes Caravan Health for 10 months Includes Caravan Health for 10 months 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin 8#9--> 2022 Key Metrics IHE Volume ECS bundled payments: Program size Savings rate Caravan ACO lives signifyhealth 2.390 to 2.420 M +$500M to $1B +25-50 bps Driven by strong customer demand Over 2021 weighted average program size Historical norm >500,000 lives under Members for which ACO manages total management cost of care, which drives revenue opportunity 9#10--> Projected drivers of future performance Strong customer IHE demand in Home and Community Services Acquisition of Caravan Health providing entry into MSSP through collaborative ACOS • ECS program size projected to rebound in 2022 ECS savings rate improvement ● ● ● Expansion of synergistic Transition to Home services • Investments to support service expansion through Partner Program Investments in non-BPCI-A Episodes of Care Services to drive chronic condition episode adoption and network expansion ● ● • Possible acquisitions to add functionality and innovation to our platform ● signifyhealth. 10#11Appendix signifyhealth. 11#12--> Reconciliation from GAAP Net (Loss) Income to Adjusted EBITDA $ in millions signifyhealth. Net income (loss) Interest expense Loss on extinguishment of debt Income tax expense (benefit) Depreciation and amortization Other expense (income), net Asset impairment Equity-based compensation Customer equity appreciation rights Transaction-related expenses SEU expense Other(1) Adjusted EBITDA Adjusted EBITDA Margin Year Ended December 31 2021 9.9 21.7 5.0 4.2 70.7 2.8 11.2 12.9 19.7 9.9 1.7 1.5 171.2 22.1% 2020 (14.5) 22.2 0.9 62.3 9.0 0.8 12.1 12.4 15.2 ‒‒ 4.5 124.9 20.5% 3 Months December 31 2021 32.4 4.2 7.9 19.1 (40.8) 11.2 3.4 4.9 0.4 (0.3) (2.2) 40.2 22.2% 2020 0.7 6.0 0.4 16.3 2.1 0.8 2.1 4.9 4.4 -- 1.2 38.9 20.2% 1) Other includes remeasurement of contingent consideration, non-recurring expenses, including those associated with one-time costs related to the COVID-19 pandemic, the closure of certain facilities, the sale of certain assets and the early termination of certain contracts. 12